Widespread adaptation of liquid biopsy for the early detection of cancer has yet to reach
clinical utility. Circulating tumor DNA is commonly detected though the presence of genetic …

Novel drugs, drug sequences and combinations have improved the outcome of prostate
cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and …

Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole …

Liquid biopsy has been established as a powerful, minimally invasive, tool to detect clinically
actionable aberrations across numerous cancer types in real-time. With the development of …

Abstract Background Prostate cancer (PCa) has the highest incidence rates of cancers in
men in western countries. Unlike several other types of cancer, PCa has few genetic drivers …

Abstract N6-methyladenosine (m 6 A) is the richest modification in mammalian messenger
RNAs (mRNAs), and exerts key roles in many biological processes, including cancer …

Tumor DNA circulates in the plasma of cancer patients admixed with DNA from
noncancerous cells. The genomic landscape of plasma DNA has been characterized in …

The process of DNA CpG methylation has been extensively investigated for over 50 years
and revealed associations between changing methylation status of CpG islands and gene …

Objective The prostate is metabolically unique: it produces high levels of citrate for secretion
via a truncated tricarboxylic acid (TCA) cycle to maintain male fertility. In prostate cancer …

It remains elusive whether some of the associations identified in genome-wide association
studies of prostate cancer (PrCa) may be due to regulatory effects of genetic variants on …